We also observed that a small molecule proteasome inhibitor bortezomib used for multiple myeloma treatment upregulates IRF6 and BLNK in detached ErbB2-positive breast cancer cells and kills them in a BLNK-dependent manner (Fig. 7). Here, ERBB2 is linked to breast cancer.